In a bid to capitalize on the increasing prevalence of cannabis consumption in the US, pharmaceutical companies have introduced a new pill that claims to combat marijuana addiction. The experimental drug, AEF-0117, has shown promise in a small trial by reducing the addictive impact of THC, the primary psychoactive compound in cannabis. While the study published in the journal Nature Medicine may appear encouraging at first glance, a closer examination raises several concerns about the motives behind such pharmaceutical interventions.
Low-dose THC beverages typically contain somewhere between 2 and 5 mg of THC per serving.…
A few dozen strangers answered one question, and here's what they told me. Cannabis rarely…
Federal officials admitted under oath at the DEA marijuana rescheduling hearing that the 54-year-old test…
Discover why Donald Trump lost the 2026 midterms, how the hemp and cannabis industries survived…
On October 29, Fox News ran a column by Dr. Marc Siegel, the network’s senior medical…
Is cannabis a miracle cure or a gateway to ruin? We break down the latest…